Targeting a pathway to overcome resistance in lung cancer treatment
Official title: Targeting the HGF-MET-TWIST1 pathway to overcome EGFR TKI resistance
Funded at Ohio State University · NIH-11291045 · Data updated 2026-11-12
This study is looking at how some lung cancer cells stop responding to a common treatment and is testing a new approach to help make that treatment work better again for patients with specific gene changes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | March 1, 2025 |
| Project end | December 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $142,177 |
| NIH project number | 7R01CA244270-06 |
| Project ID | NIH-11291045 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with EGFR mutant non-small cell lung cancer who have experienced resistance to EGFR TKIs.
✕Less likely to help
Patients without EGFR mutations or those who have not undergone treatment with EGFR TKIs may not benefit from this research.
What this research studies
This research investigates how certain cancer cells develop resistance to a common treatment for non-small cell lung cancer (NSCLC) that has mutations in the EGFR gene. It focuses on the HGF-MET-TWIST1 signaling pathway, which has been identified as a key player in this resistance. By inhibiting TWIST1, the researchers aim to restore the effectiveness of EGFR tyrosine kinase inhibitors (TKIs) in patients whose tumors have become resistant. The study will explore the mechanisms behind this resistance and test new treatment strategies in laboratory settings.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve outcomes for patients with resistant forms of lung cancer.
How similar studies have gone: Previous research has shown promise in targeting similar pathways to overcome treatment resistance in cancer, indicating potential for success in this approach.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Burns, Timothy F. — Ohio State University
- Study coordinator: Burns, Timothy F.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.